Directors Deals 

Alliance Pharma founder sells down

Alliance Pharma founder sells down

When we last wrote about Alliance Pharma (APH), the shares had enjoyed a good run. But the stock, now trading at 63.6p, has actually lost around close to 38 per cent of its value since a mid-June 12-month peak of 102p. That could be due to a host of regulatory and accounting changes which will lead to – in broker Numis’s words – “a step-up in its cost base by £0.7m to comply with these new regimes”. It doesn’t sound like much at face value, but it forced analysts to lower FY2019 adjusted pre-tax profit forecasts by 4 per cent and by 2.6 per cent in FY2020.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now